Argyle Capital Management Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Argyle Capital Management reduced its stake in Merck & Co. by 0.13% during the most recent quarter end. The investment management company now holds a total of 96,256 shares of Merck & Co. which is valued at $5,640,602 after selling 125 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Merck & Co. makes up approximately 2.33% of Argyle Capital Management’s portfolio.

Other Hedge Funds, Including , First Dallas Securities boosted its stake in MRK in the latest quarter, The investment management firm added 301 additional shares and now holds a total of 13,777 shares of Merck & Co. which is valued at $807,332. Merck & Co. makes up approx 0.60% of First Dallas Securities’s portfolio.Rehmann Capital Advisory Group reduced its stake in MRK by selling 4,764 shares or 18.76% in the most recent quarter. The Hedge Fund company now holds 20,633 shares of MRK which is valued at $1,209,094. Merck & Co. makes up approx 0.22% of Rehmann Capital Advisory Group’s portfolio.Jfs Wealth Advisors reduced its stake in MRK by selling 60 shares or 0.58% in the most recent quarter. The Hedge Fund company now holds 10,309 shares of MRK which is valued at $604,107. Merck & Co. makes up approx 0.16% of Jfs Wealth Advisors’s portfolio.Sadoff Investment Management reduced its stake in MRK by selling 226 shares or 5.22% in the most recent quarter. The Hedge Fund company now holds 4,105 shares of MRK which is valued at $241,456. Merck & Co. makes up approx 0.03% of Sadoff Investment Management’s portfolio.First Premier Bank boosted its stake in MRK in the latest quarter, The investment management firm added 2,950 additional shares and now holds a total of 19,537 shares of Merck & Co. which is valued at $1,159,521. Merck & Co. makes up approx 0.88% of First Premier Bank’s portfolio.

Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *